• About Us
  • Accomplishing Our Mission
  • A Message from our Founder
  • Board of Directors
  • Staff
  • Funding Sources
• R&D Programs
  • Leishmaniasis
  • Tuberculosis
  • Malaria
  • Leprosy
  • Chagas Disease
  • Chlamydia
  • Buruli Ulcer
• Capabilities
  • Antigen Discovery
  • Preclinical Biology
  • Process Sciences
  • Clinical Development
  • Adjuvants and Delivery
• Collaborate
  • Collaborations
• News

Sitemap

• Home
  • Interns
• About Us
  • Accomplishing Our Mission
  • A Message from our Founder
  • Board of Directors
  • Staff
  • Funding Sources
• R&D Programs
  • TB Drug 2
  • TB Drug 3
  • TB Drug 4
  • TB Drug 5
  • TB Drug 6
  • TB Drug 7
  • TB Vaccine 2
  • Tuberculosis Drug Discovery
  • Tuberculosis Vaccine Development
  • Leishmaniasis
  • Tuberculosis
  • Malaria
  • Leprosy
  • Chagas Disease
  • Chlamydia
  • Buruli Ulcer
• Capabilities
  • Antigen Discovery
  • Preclinical Biology
  • Process Sciences
  • Clinical Development
  • Adjuvants and Delivery
• Collaborate
  • Collaborations
• Site Map
• News
  • 3M
  • Alumnus
  • Chembio
  • Chembio2
  • Closing In
  • Davis
  • FrontFlu
  • IDRI-IDC GLA
  • Gates
  • Gates2006
  • GatesVL
  • Murdock
  • Murdock2
  • NY Trust
  • NanoPass
  • NewLeadershipTB
  • Pandemic
  • ResearchAmerica
  • SVP
  • Seattle
  • SudanTrial
  • Tackling
  • U01Coler

• Home
• About Us
• R&D Programs
• Capabilities
• Collaborate
• Site Map
• News

1124 Columbia Street Suite 400, Seattle, Washington 98104
office@idri.org   |   P: (206) 381-0883  |   F: (206) 381-3678
Copyright © 1993-2008 Infectious Disease Research Institute

Website design by AtoZ Studio, Seattle